6 Aptamers for Targeted Therapy
165
11. Ruckman J, Green Ls, Beeson J,Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L,
Janji´ c N (1998) 2’-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of
vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGFinduced vascular permeability through interactions requiring the exon 7-encoded domain. J
Biol Chem 273 (32):20556–20567
12. Shaw JP, Kent K, Bird J, Fishback J, Froehler B (1991) Modified deoxyoligonucleotides stable
to exonuclease degradation in serum. Nucleic Acids Res 19(4):747–750
13. Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW (1999) Detection
and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotideaptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732(1):203–212
14. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf
JL, Gill SC, Bendele RA (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus
monkeys. Pharm Res 17(12):1503–1510
15. Liu SC, Alomran R, Chernikova SB, Lartey F, Stafford J, Jang T, Merchant M, Zboralski D,
Zollner S, Kruschinski A, Klussmann S, Recht L, Brown JM (2014) Blockade of SDF-1 after
irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro Oncol
16(1):21–28
16. Rosenfeld PJ, Brown Dm, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA
Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl
J Med 355(14):1419–1431
17. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A,
Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G,
Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, View, Groups VS (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology
119(12):2537–2548
18. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP,
Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the
efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular
neovascularization. Am J Pathol 168(6):2036–2053
19. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke
S, Meengs B, Brody J, Presnell S, Hamacher NB, Lantry M, Wolf A, Bukowski T, Rosler
R, Yen C, Anderson-Haley M, Brasel K, Pan Q, Franklin H, Thompson P, Dodds M, Underwood S, Peterson S, Sivakumar PV, Snavely M (2010) A dual-targeting PDGFRbeta/VEGF-A
molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity
in vitro and in vivo. MAbs 2(1):20–34
20. Jackson TL, Boyer D, Brown DM, Chaudhry N, Elman M, Liang C, O’Shaughnessy D,
Parsons EC, Patel S, Slakter JS, Rosenfeld PJ (2017) Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 dose-escalation study. JAMA Ophthalmol
135(7):761–767
21. Green LS, Jellinek D, Jenison R, Ostman A, Heldin CH, Janjic N (1996) Inhibitory DNA
ligands to platelet-derived growth factor B-chain. Biochemistry 35(45):14413–14424
22. Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic
N (1999) Novel approach to specific growth factor inhibition in vivo: antagonism of plateletderived growth factor in glomerulonephritis by aptamers. Am J Pathol 154(1):169–179
23. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, Yamada H, Yamada E, Derevjanik NL, LaRochelle W, Zack DJ, Campochiaro PA (2000) Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol
157(3):995–1005
24. Feitelson E (2005) Political economy of groundwater exploitation: the israeli case. Int J Water
Resour Dev 21(3):413–423
25. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, Group
AS (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
N Engl J Med 355(14):1432–1444
165
11. Ruckman J, Green Ls, Beeson J,Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L,
Janji´ c N (1998) 2’-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of
vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGFinduced vascular permeability through interactions requiring the exon 7-encoded domain. J
Biol Chem 273 (32):20556–20567
12. Shaw JP, Kent K, Bird J, Fishback J, Froehler B (1991) Modified deoxyoligonucleotides stable
to exonuclease degradation in serum. Nucleic Acids Res 19(4):747–750
13. Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW (1999) Detection
and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotideaptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732(1):203–212
14. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf
JL, Gill SC, Bendele RA (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus
monkeys. Pharm Res 17(12):1503–1510
15. Liu SC, Alomran R, Chernikova SB, Lartey F, Stafford J, Jang T, Merchant M, Zboralski D,
Zollner S, Kruschinski A, Klussmann S, Recht L, Brown JM (2014) Blockade of SDF-1 after
irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro Oncol
16(1):21–28
16. Rosenfeld PJ, Brown Dm, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA
Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl
J Med 355(14):1419–1431
17. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A,
Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G,
Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, View, Groups VS (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology
119(12):2537–2548
18. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP,
Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the
efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular
neovascularization. Am J Pathol 168(6):2036–2053
19. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke
S, Meengs B, Brody J, Presnell S, Hamacher NB, Lantry M, Wolf A, Bukowski T, Rosler
R, Yen C, Anderson-Haley M, Brasel K, Pan Q, Franklin H, Thompson P, Dodds M, Underwood S, Peterson S, Sivakumar PV, Snavely M (2010) A dual-targeting PDGFRbeta/VEGF-A
molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity
in vitro and in vivo. MAbs 2(1):20–34
20. Jackson TL, Boyer D, Brown DM, Chaudhry N, Elman M, Liang C, O’Shaughnessy D,
Parsons EC, Patel S, Slakter JS, Rosenfeld PJ (2017) Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 dose-escalation study. JAMA Ophthalmol
135(7):761–767
21. Green LS, Jellinek D, Jenison R, Ostman A, Heldin CH, Janjic N (1996) Inhibitory DNA
ligands to platelet-derived growth factor B-chain. Biochemistry 35(45):14413–14424
22. Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic
N (1999) Novel approach to specific growth factor inhibition in vivo: antagonism of plateletderived growth factor in glomerulonephritis by aptamers. Am J Pathol 154(1):169–179
23. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, Yamada H, Yamada E, Derevjanik NL, LaRochelle W, Zack DJ, Campochiaro PA (2000) Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol
157(3):995–1005
24. Feitelson E (2005) Political economy of groundwater exploitation: the israeli case. Int J Water
Resour Dev 21(3):413–423
25. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, Group
AS (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
N Engl J Med 355(14):1432–1444